NEW DELHI: The Drug Controller General of India (DCGI) has approved India’s first indigenously vaccine candidate, COVAXIN, for clinical trials Phase 1 and 2 in infected people.
The vaccine was innovated by Bharat Biotech, in collaboration with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). The company has scheduled human trials for July 2020.
Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech, has said that the collaboration with NIV and ICMR was instrumental in the development of the vaccine.
The press release of the company said that the results from the pre-clinical studies have been promising and show extensive safety and effective immune response.
Along with the Bharat Biotech, five other Indian companies are working on development of a vaccine.